Sylvain Chemtob

This inventor holds 13 USPTO granted patents and 10 published patent applications, plus 6 CIPO patents and 6 EPO patents. Top assignees: Valorisation-Recherche, Limited Partnership, Valorisation Hsj, Limited Partnership, Hopital Sainte-Justine. Active years: 1999-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sylvain Chemtob. Retrieved from https://idiyas.com/inventor/sylvain-chemtob

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 10)

% Patents Active = 38.5

CIPO Patents = 6 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 58(Granted Patents)

Location History:

Montréal, CA (2001 - 2008)
Côte St-Luc, CA (2008 - 2013)
Montreal, CA (1999 - 2015)
Cote St-Luc, CA (2014 - 2017)

Company Filing History:

4 out of 43

Valorisation-Recherche, Limited Partnership

patents

3 out of 12

Valorisation Hsj, Limited Partnership

patents

2 out of 13

Hopital Sainte-Justine

patents

4. 2 out of 29

Theratechnologies Inc.

patents

5. 2 out of 189

Universitéde Montreal

patents

6. 1 out of 3

Hospital Sainte-Justine

patents

7. 1 out of 14

Rsem, Limited Partnership

patents

8. 1 out of 1

Valo Hsj, Limited Partnership

patent

9. 1 out of 2

Valorisation Hsj, Societe En Commandite

patents

10. 1 out of 1

Valorisation-Rechereche Société En Commandite

patent

11. 2 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2017

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9708370 - Azapeptides as CD36 binding compounds (2017-07-18),

2. 9115171 - Azapeptides as CD36 binding compounds (2015-08-25),

3. 9073963 - [object Object] (2015-07-07),

4. 8993515 - Peptidomimetics comprising N-amino cyclic urea residues and uses thereof (2015-03-31),

5. 8802818 - Prostaglandin-F2 alpha receptor modulators and uses thereof (2014-08-12),

6. 8618054 - Interleukin-1 receptor antagonists, compositions, and methods of treatment (2013-12-31),

7. 8435954 - Azapeptides as CD36 binding compounds (2013-05-07),

8. 7521530 - [object Object] (2009-04-21),

9. 7442763 - Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis (2008-10-28),

10. 7432341 - Cytokine receptor modulators and method of modulating cytokine receptor activity (2008-10-07),

11. 6984719 - Peptide antagonists of prostaglandin F2α receptor (2006-01-10),

12. 6300312 - Antagonists of G-protein-coupled receptor (2001-10-09),

13. 5955575 - Antagonists of G-protein-coupled receptor (1999-09-21),

Title: The Innovative Journey of Sylvain Chemtob

Introduction: Sylvain Chemtob, based in Côte St-Luc, Canada, is a prominent inventor known for his contributions in the field of azapeptide compounds. With a remarkable portfolio of 13 patents, he has demonstrated an unwavering commitment to scientific innovation and research in biochemistry.

Latest Patents: Among his latest patents, Chemtob has developed groundbreaking azapeptides that serve as CD36 binding compounds. His notable patent includes an azapeptide compound of Formula I: A-(Xaa)-N(R)—N(R)—C(O)-(Xaa')-B, which showcases his innovative approach to therapeutic discoveries.

Career Highlights: Throughout his career, Sylvain Chemtob has worked with esteemed organizations such as Valorisation-Recherche Limited Partnership and Valorisation HSJ Limited Partnership. His expertise in the field has enabled him to push the boundaries of current scientific understanding.

Collaborations: Collaboration has been an essential aspect of Chemtob's work, notably with talented individuals such as William A. Lubell and Krishna G. Peri. His ability to work alongside fellow researchers highlights the synergy needed to achieve significant breakthroughs in innovation.

Conclusion: Sylvain Chemtob's dedication to research and innovation has led to numerous patents and collaborations that greatly enrich the field of biochemistry. As he continues to explore the potential of azapeptide compounds, the impact of his work will undoubtedly resonate throughout the scientific community.

Profile summary based on public USPTO records.